Introduction
============

HIV-positive MSM are increasingly at risk for developing anal squamous cell carcinoma compared to the general population \[[@R1]\]. Clinics have been set up to detect precursor lesions of anal squamous cell carcinoma, called squamous intraepithelial lesions (SIL) \[[@R2]--[@R5]\]. High-resolution anoscopy (HRA)-guided biopsies are the gold standard for identifying anal SIL. SIL is histopathologically graded anal intraepithelial neoplasia (AIN) 1, 2, or 3 and categorized as low-grade SIL (LSIL; AIN1) or high-grade SIL (HSIL; AIN 2 and 3). The prevalence of histological HSIL (hHSIL) in HIV-positive MSM is around 40% \[[@R6]\] and, as HRA is a costly and cumbersome procedure, more stringent screening criteria for HIV-positive MSM receiving HRA are needed.

Anal cytology can be used for the detection of HSIL (cytological HSIL), but its use is limited by low sensitivity \[[@R7]--[@R11]\]. Several studies have identified risk factors for hHSIL in HIV-positive MSM, but results are not always consistent and studied populations were often relatively small \[[@R12]--[@R15]\], limiting their potential to identify the patients at highest risk for hHSIL.

We investigated potential demographic and HIV-related risk factors for the presence of histopathologically proven intra- and perianal HSIL in 1681 HIV-positive MSM screened by HRA in Amsterdam, the Netherlands.

Methods
=======

Patients and setting
--------------------

HIV-positive MSM visiting one of three outpatient HIV clinics in Amsterdam, the Netherlands, were offered AIN screening by their HIV-treating physician. The only exclusion criterion was a life expectancy of less than 12 months. HRA was performed by individually trained anoscopists, did not include anal cytology, sexually transmitted disease (STD), or human papillomavirus (HPV) testing and consisted of a digital rectal examination followed by intra- and perianal inspection with a colposcope (ZEISS opmi pico surgical microscope; Oberkochen, Baden-Württemberg, Germany) after repeatedly applying acetic acid (3--5% solution) and staining with Lugol\'s iodine when indicated. Lesions suspicious for SIL were biopsied and graded by pathologists specialized in SIL. In clinics A and C, pathologists used p16 staining for AIN2 graded biopsies, as described by the College of American Pathologists in The Lower Anogenital Squamous Terminology standardization project, whereas, in clinic B, p16 staining was not always used in accordance to the College of American Pathologists Lower Anogenital Squamous Terminology criteria \[[@R16]\]. The highest grade biopsy defined the overall diagnosis.

Data were extracted from the clinical records by two of the investigators (MLSH and EM); behavioral data were patient self-reported to the clinician. HIV-related data were obtained from the Stichting HIV monitoring database \[[@R17]\]. Data collection were performed using the OpenClinica open source software, version 3.6 (OpenClinica LLC and collaborators, Waltham, Massachusetts, USA).

The study (ref. W15_047 \# 15.0058) was approved by the Medical Ethics Review Committee of the Academic Medical Center, Amsterdam, the Netherlands.

Statistical analysis
--------------------

Only data of the first HRA of each participant were included. Baseline characteristics of the study population were explored using descriptive statistics, comparing characteristics between participants with no dysplasia, LSIL and HSIL using χ^2^ test for categorical data and one-way analysis of variance, and Kruskal--Wallis test for continuous data.

Assessed outcome variables were: HSIL vs. no SIL, HSIL-AIN2 vs. no SIL, HSIL-AIN3 vs. no SIL, and HSIL vs. no HSIL. Five demographic and seven HIV-related variables were included in univariable logistic regression analysis (Suppl. Table 1). For CD4^+^ cell count and HIV viral load measurements, the measurements closest to the date of HRA were selected. Years living with viral suppression was defined as having a viral load of less than 200 copies/ml in tests from August 1999 onwards, and allowing for one blip in viral load below 400 copies/ml between measurements with viral load less than 200 copies/ml \[[@R18]\]. For samples tested prior to August 1999 the cut-off of detectability of the laboratory assay was the cut-off used to define viral suppression.

Multivariable logistic regression analysis was used to determine independent risk factors for HSIL among HIV-positive MSM. All variables that were significantly associated in univariable logistic regression analysis with HSIL diagnosis (at *P* \< 0.2, Wald test) were included in the multivariable analysis, as well as the following a priori selected parameters (risk factors for HSIL in other studies \[[@R10],[@R19]--[@R22]\]): age at time of HRA, a history of at least one AIDS defining illness, nadir CD4^+^ cell count, current CD4^+^ cell count, and years living with viral suppression. A backward selection method was used to create a parsimonious model in which a priori selected variables were forced. We conducted multilevel multivariable logistic regression analyses to correct for potential similarities of participants within each clinic. Multicollinearity was tested with the variance inflation factor and if present, the most objective measurable variable remained in the model, whereas the other variable was dropped. However, the effect of this exclusion was checked in a sensitivity analysis. To assess whether the effect of risk factors differed by clinic, interaction was tested in the multivariable model. Also, risk factors for HSIL were assessed separately for intra-anal and perianal HSIL. Variables were considered significantly associated when *P* value was less than 0.05. Statistical analyses were performed using Stata (version 13.1; Stata Corp, College Station, Texas, USA).

Results
=======

Characteristics of study population
-----------------------------------

Between 12 February 2008 and 24 November 2015, 1681 HIV-positive MSM underwent their first HRA. Potential risk factors for histological (H)SIL of 311 HIV-positive MSM have been previously described \[[@R15]\]. Three participants were excluded based on the diagnosis of SCC (two intra-anal and one perianal SCC). The mean age was 49 years (SD 9.6) and 96% of participants used combination antiretroviral therapy (cART). Median duration of cART use was 7.8 years \[interquartile range (IQR) 4.0--12.4\], median nadir CD4^+^ cell count was 220 cells/μl (IQR 130--320), and median current CD4^+^ cell count was 620 cells/μl (IQR 480--790). Only 354 (22%) participants had at least one AIDS-defining illness prior to HRA (Table [1](#T1){ref-type="table"}). There were some statistically significant (but clinically not important) differences between patients from the three clinics (Suppl. Table 2).

Of the 1678 HIV-positive MSM, 396 (24%) were diagnosed with AIN1, 289 (17%) with AIN2, and 208 with AIN3 (12%). The prevalence of HSIL was 30% (497/1678 participants). The prevalence of HSIL did not differ significantly between clinics (Suppl. Table 2). Compared to participants with no dysplasia, participants with LSIL and HSIL were younger (*P* \< 0.001), had more sex partners in the preceding 6 months (*P* = 0.016), had a lower number of years on cART (*P* \< 0.001), had a different distribution of nadir CD4^+^ cell counts (*P* = 0.005), had more often a detectable HIV viral load (*P* = 0.001), and had less years living with viral suppression (*P* \< 0.001; Table [1](#T1){ref-type="table"} ).

Univariable logistic regression analyses
----------------------------------------

Associated variables for HSIL vs. no SIL in univariable logistic regression analyses were age, duration of cART use, having had an STD in the preceding 6 months, HIV plasma viral load, and number of years living with viral suppression. Nadir and current CD4^+^ cell count were not associated with HSIL. Univariable associations between risk factors and outcome were largely similar between the four outcome measures (Suppl. Table 1).

Multivariable logistic regression analyses
------------------------------------------

In multivariable logistic regression analysis, nested within clinic and comparing HSIL vs. no SIL, increasing age \[adjusted odds ratio (aOR) 0.82, 95% confidence interval (CI) 0.70--0.94; *P* = 0.006\], and years living with suppressed viral load were significantly protective for HSIL \[1--5 years viral suppression aOR 0.52 (95% CI 0.34--0.80), 5.01--10 years viral suppression aOR 0.47 (95% CI 0.29--0.74), \>10 years viral suppression aOR 0.54 (0.34--0.87), all compared to less than 1 year viral suppression, *P* = 0.009\]. Outcome measures HSIL-AIN2 vs. no SIL, HSIL-AIN3 vs. no SIL, and HSIL vs. no HSIL yielded similar results (Table [2](#T2){ref-type="table"}).

Based on multicollinearity, we excluded a priori cART use, HIV viral load and duration of cART use because this is largely represented in number of years living with viral suppression. We reran the model including duration of cART use instead of years living with viral suppression, yielding similar results. None of the interaction terms were significant, suggesting that the effect of the included risk factors did not vary by clinic (data not shown).

Additionally, we assessed risk factors for intra- and perianal HSIL vs. no SIL separately. Intra-anal HSIL showed results comparable to the overall model. Only being a current smoker was found to be a significant risk factor of perianal HSIL in multilevel multivariable logistic regression analyses \[previously smoked aOR 2.41 (95% CI 0.77--7.57), current smoker aOR 4.90 (95% CI 1.80--13.35), compared to participants who never smoked, *P* = 0.006; Supplementary Table 3\].

Discussion
==========

We analyzed potential risk factors for anal HSIL (AIN2--3) in 1678 HIV-positive MSM. Of five demographic and seven HIV-related potential risk factors, only increasing age and years living with suppressed viral load were significantly protective for HSIL vs. no SIL. Sensitivity analyses, including duration of cART use instead of duration of viral suppression, showed a similar relation.

In contrast to our results, several smaller studies, with less than 400 patients each, reported various demographic and HIV-related risk factors that significantly increased the risk for anal hHSIL: the number of specific HPV types and current use of cART \[[@R13]\], increasing age and CD4^+^ cell counts less than 50/μl before starting cART \[[@R12]\], and smoking \[[@R23],[@R24]\]. We found smoking to be a risk factor, but for perianal HSIL only. We also confirmed that duration of cART use showed a reduced risk for hHSIL \[[@R12],[@R25]\]. Living more than 1 year with viral suppression might reduce the risk for hHSIL as it could be a proxy for immune restoration over time. We have no good explanation how older age could be protective for anal HSIL.

The strength of this study is that it reports nearly 1700 patients from three HIV clinics, using hHSIL as an endpoint. This allowed for an extensive multivariable analysis without constraints in the number of covariates.

A limitation of our study is that no data were collected on anal HPV infections, but given that 95% of all HIV-positive MSM have anal HPV present, the value of this risk factor is debatable \[[@R13],[@R26]\]. More specifically, HPV16 testing might be considered to have more discriminatory power, but given that HPV16 was the causative HPV type in only 60% of anal carcinomas in HIV-positive MSM in another study by our group \[[@R27]\], 40% of potential anal carcinomas would be missed. Also, patient populations differed significantly between clinics, which may be explained by differences in calendar year of starting with HRA screening and by the large study populations, easily leading to statistically significant but not clinically important differences. Furthermore, multiple anoscopists performed the HRAs, and given the long learning curve for HRA, some HSIL lesions may have been missed \[[@R28],[@R29]\]. Also, in clinic B p16 staining was not always used to confirm AIN2 graded biopsies. Finally, social desirability bias might have occurred for self-reported STDs and sexual behavior.

Young HIV-positive MSM without viral suppression are statistically at highest risk for HSIL, but given the high prevalence of HSIL among all virally suppressed men, we advise that all HIV-positive MSM should be screened for the presence of anal HSIL.
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###### 

Characteristics of the study population of the anal intraepithelial neoplasia cohort study by histological high-grade squamous intraepithelial lesion status, Amsterdam 2008--2015 (*N* = 1678).

                                                                                                                               Total (*N* = 1678)   No dysplasia (*N* = 785)   LSIL (*N* = 396)   HSIL (*N* = 497)                                           
  ---------------------------------------------------------------------------------------------------------------------------- -------------------- -------------------------- ------------------ ------------------ ----- ------------- ----- ------------- ---------
  Demographic variables                                                                                                                                                                                                                                      
   Age in years (mean/SD)[^a^](#TF1-1){ref-type="table-fn"}                                                                    49                   (9.6)                      50                 (9.4)              48    (10.0)        48    (9.3)         \<0.001
   Continent of birth[^b^](#TF1-2){ref-type="table-fn"}                                                                                                                                                                                                      0.710
    Europe                                                                                                                     1279                 82%                        566                82%                305   81%           408   84%           
    Americas                                                                                                                   188                  12%                        83                 12%                50    13%           55    11%           
    Oceania                                                                                                                    11                   1%                         5                  1%                 1     0%            5     1%            
    Asia                                                                                                                       46                   3%                         22                 3%                 14    4%            10    2%            
    Africa                                                                                                                     28                   2%                         13                 2%                 8     2%            7     1%            
   Smoking status[^c^](#TF1-3){ref-type="table-fn"}                                                                                                                                                                                                          0.481
    Never smoked                                                                                                               598                  38%                        275                38%                145   39%           178   39%           
    Previously smoking                                                                                                         379                  24%                        191                26%                83    22%           105   23%           
    Currently smoking                                                                                                          577                  37%                        256                35%                145   39%           176   38%           
   Number of sex partners in the preceding 6 months (median/IQR)[^d^](#TF1-4){ref-type="table-fn"}                             2                    (1--6)                     1                  (1--5)             2     (1--6)        2     (1--7)        0.016
   Number of sex partners in the preceding 6 months[^d^](#TF1-4){ref-type="table-fn"}                                                                                                                                                                        0.166
    0--1                                                                                                                       598                  49%                        295                52%                141   48%           162   44%           
    2--5                                                                                                                       304                  25%                        131                23%                77    26%           96    26%           
    ≥6                                                                                                                         316                  26%                        136                24%                73    25%           107   29%           
   Had an STD in the preceding 6 months                                                                                                                                                                                                                      0.066
    No                                                                                                                         1586                 95%                        750                96%                376   95%           460   93%           
    Yes                                                                                                                        92                   5%                         35                 4%                 20    5%            37    7%            
  HIV-related variables                                                                                                                                                                                                                                      
   Currently using cART[^e^](#TF1-5){ref-type="table-fn"}                                                                                                                                                                                                    0.124
    No                                                                                                                         73                   4%                         26                 3%                 23    6%            24    5%            
    Yes                                                                                                                        1580                 96%                        743                97%                368   94%           469   95%           
   Duration of cART use in years (median/IQR)[^f^](#TF1-6){ref-type="table-fn"}                                                7.8                  (4.0--12.4)                8.9                (4.8--12.8)        6.6   (3.6--11.8)   7.5   (3.1--12.3)   \<0.001
   CD4^+^ T-cell count cells/μl (median/IQR)[^g^](#TF1-7){ref-type="table-fn"}                                                 620                  (480--790)                 620                (480--800)         605   (450--780)    630   (490--800)    0.236
   CD4^+^ T-cell count cells/μl [^g^](#TF1-7){ref-type="table-fn"}                                                                                                                                                                                           0.423
    \<350                                                                                                                      168                  10%                        75                 10%                48    12%           45    9%            
    350--500                                                                                                                   323                  20%                        153                20%                81    21%           89    18%           
    \>500                                                                                                                      1163                 70%                        541                70%                265   67%           357   73%           
   Nadir CD4^+^ T-cell count cells/μl (median/IQR)[^h^](#TF1-8){ref-type="table-fn"}                                           220                  (130--320)                 220                (130--310)         220   (120--320)    222   (130--351)    0.357
   Nadir CD4^+^ T-cell count cells/μl[^h^](#TF1-8){ref-type="table-fn"}                                                                                                                                                                                      0.005
    \<100                                                                                                                      315                  19%                        146                19%                79    20%           90    18%           
    100--199                                                                                                                   368                  22%                        168                22%                86    22%           114   23%           
    200--349                                                                                                                   624                  38%                        315                41%                153   39%           156   32%           
    \>350                                                                                                                      344                  21%                        138                18%                76    19%           130   26%           
   HIV plasma viral load copies/ml (median/IQR)[^i^](#TF1-9){ref-type="table-fn"}                                              20                   (1--40)                    20                 (1--40)            20    (1--40)       20    (1--40)       0.211
   HIV viral load copies/ml[^i^](#TF1-9){ref-type="table-fn"}                                                                                                                                                                                                0.001
    \<50                                                                                                                       1347                 89%                        620                92%                315   85%           412   88%           
    ≥50                                                                                                                        161                  11%                        51                 8%                 56    15%           54    12%           
   Years living with viral suppression (median/IQR)[^j^](#TF1-10){ref-type="table-fn"}^,^[^k^](#TF1-11){ref-type="table-fn"}   6.3                  (2.6--11.1)                7.2                (3.7--11.8)        5.1   (2.0--10.1)   5.9   (1.9--11.0)   \<0.001
   Years living with viral suppression[^j^](#TF1-10){ref-type="table-fn"}^,^[^k^](#TF1-11){ref-type="table-fn"}                                                                                                                                              \<0.001
    \<1 year[^l^](#TF1-12){ref-type="table-fn"}                                                                                203                  14%                        61                 9%                 57    16%           85    18%           
    1--5 years                                                                                                                 411                  28%                        172                26%                117   33%           122   26%           
    5.01--10 years                                                                                                             393                  27%                        187                28%                94    26%           112   24%           
    \>10 years                                                                                                                 476                  32%                        238                36%                92    26%           146   31%           
   Having had an AIDS defining illness^m,n^                                                                                                                                                                                                                  0.803
    No                                                                                                                         1280                 78%                        575                78%                313   79%           392   79%           
    Yes                                                                                                                        354                  22%                        166                22%                83    21%           105   21%           
  Clinic                                                                                                                                                                                                                                                     
   Clinic where HRA was done                                                                                                                                                                                                                                 0.008
    Clinic A                                                                                                                   710                  42%                        334                43%                163   41%           213   43%           
    Clinic B                                                                                                                   674                  40%                        288                37%                176   44%           210   42%           
    Clinic C                                                                                                                   294                  17%                        163                21%                57    14%           74    15%           
  AIN diagnosis                                                                                                                                                                                                                                              
   No dysplasia                                                                                                                785                  47%                                                                                                      
   AIN1                                                                                                                        396                  24%                                                                                                      
   AIN2                                                                                                                        289                  17%                                                                                                      
   AIN3                                                                                                                        208                  12%                                                                                                      
  Location HSIL                                                                                                                                                                                                                                              
   Intra-anal HSIL                                                                                                             474                  28%                                                                                                      
   Perianal HSIL                                                                                                               46                   3%                                                                                                       

AIN, anal intraepithelial neoplasia; cART, combination antiretroviral therapy; HSIL, high-grade squamous intraepithelial lesion; IQR, interquartile range; LSIL, low-grade squamous intraepithelial lesion; STD, sexually transmitted disease.

^a^Total -- 1 missing; no dysplasia -- 1 missing; LSIL -- 0 missings; HSIL -- 0 missings.

^b^Total -- 126 missings; no dysplasia -- 96 missings; LSIL -- 18 missings; HSIL -- 12 missings.

^c^Total -- 124 missings; no dysplasia -- 63 missings; LSIL -- 23 missings; HSIL -- 38 missings.

^d^Total -- 460 missings; no dysplasia -- 223 missings; LSIL -- 105 missings; HSIL -- 132 missings.

^e^Total -- 25 missings; no dysplasia -- 16 missings; LSIL -- 5 missings; HSIL -- 4 missings.

^f^Total -- 93 missings; no dysplasia -- 39 missings; LSIL -- 27 missings; HSIL -- 27 missings.

^g^Total -- 24 missings; no dysplasia -- 16 missings; LSIL -- 2 missings; HSIL -- 6 missings.

^h^Total -- 27 misisngs; no dysplasia -- 18 missings; LSIL -- 2 missings; HSIL -- 7 missings.

^i^Total -- 170 missings; no dysplasia -- 113 missings; LSIL -- 26 missings; HSIL -- 31 missings.

^j^Total -- 196 missings; no dysplasia -- 127 missings; LSIL -- 36 missings; HSIL -- 33 missings.

^k^Viral suppression was defined as having a viral load of less than 200 in tests from 1 August 1999 onwards allowing for a onetime blip in viral load between 200 and 400 copies/ml. For samples tested prior to 1 August 1999 the cut-off of detectability of the laboratory assay that was used for that sample is the cut-off for viral suppression.

^l^Participants who never had an undetectable viral load are included in the category less than 1-year undetectable viral load.

^m^Total -- 45 missings; no dysplasia -- 44 missings; LSIL -- 0 missing; HSIL -- 1 missing.

^n^Included AIDS defining illnesses: candidiasis esophageal, Kaposi\'s sarcoma, recurrent pneumonia, chronic intestinal microsporidiosis, pneumocystis carinii pneumonia, *Mycobacterium kansasii*, pulmonary tuberculosis, chronic intestinal cryptosporidiosis, AIDS dementia complex/HIV encephalopathy, toxoplasmosis of the brain, other species/unidentified extrapulmonary mycobacterium, cytomegalovirus (CMV) retinitis, non-Hodgkin\'s lymphoma, CMV disease (other than lymph node, liver, spleen), herpes simplex virus, progressive multifocal leucoencephalopathy, extrapulmonary cryptococcosis, primary lymphoma of central nervous system, extrapulmonary tuberculosis, wasting syndrome because of HIV, disseminated or extrapulmonary histoplasmosis, visceral leishmaniasis, candidiasis of trachea/bronchi/lungs, disseminated or extrapulmonary coccidioidomycosis, extrapulmonary pneumocystis, other CDC C event.

###### 

Risk factors of anal histologically proven high-grade squamous intraepithelial lesion.

                                                                           \(1\) Multivariable logistic regression HSIL vs. no SIL[^a^](#TF2-1){ref-type="table-fn"}   \(2\) Multivariable logistic regression AIN2 vs. no SIL[^a^](#TF2-1){ref-type="table-fn"}   \(3\) Multivariable logistic regression AIN3 vs. no SIL   \(4\) Multivariable logistic regression HSIL vs. no HSIL[^a^](#TF2-1){ref-type="table-fn"}                                                                              
  ------------------------------------------------------------------------ ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- --------------------------------------------------------- -------------------------------------------------------------------------------------------- -------------- ------- ------ -------------- ------- ------ -------------- -------
  Demographic variables                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
   Age in years[^b^](#TF2-2){ref-type="table-fn"}                          0.82                                                                                        (0.70--0.94)                                                                                0.006                                                     0.79                                                                                         (0.66--0.93)   0.006   0.85   (0.70--1.04)   0.116   0.88   (0.77--1.00)   0.057
  HIV-related variables                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
   CD4^+^ T-cell count, cells/μl                                                                                                                                                                                                                                   0.427                                                                                                                                                                 0.757                         0.290                         0.397
    \<350                                                                  REF                                                                                                                                                                                                                                               REF                                                                                                                 REF                           REF                   
    350--500                                                               1.08                                                                                        (0.64--1.82)                                                                                                                                          1.05                                                                                         (0.56--1.95)           1.13   (0.55--2.30)           1.15   (0.72--1.84)   
    \>500                                                                  1.29                                                                                        (0.79--2.10)                                                                                                                                          1.18                                                                                         (0.66--2.13)           1.50   (0.77--2.91)           1.31   (0.84--2.04)   
   Nadir CD4 T-cell count, cells/μl[^c^](#TF2-3){ref-type="table-fn"}      0.97                                                                                        (0.88--1.06)                                                                                0.494                                                     1.02                                                                                         (0.92--1.14)   0.671   0.89   (0.78--1.01)   0.076   1.00   (0.92--1.09)   0.924
   Years living with viral suppression[^d^](#TF2-4){ref-type="table-fn"}                                                                                                                                                                                           0.009                                                                                                                                                                 0.070                         0.006                         0.039
    \<1 year[^e^](#TF2-5){ref-type="table-fn"}                             REF                                                                                                                                                                                                                                               REF                                                                                                                 REF                           REF                   
    1--5 years                                                             0.52                                                                                        (0.34--0.80)                                                                                                                                          0.53                                                                                         (0.32--0.86)           0.49   (0.28--0.85)           0.61   (0.42--0.88)   
    5.01--10 years                                                         0.47                                                                                        (0.29--0.74)                                                                                                                                          0.55                                                                                         (0.32--0.94)           0.34   (0.19--0.64)           0.61   (0.41--0.92)   
    \>10 years                                                             0.54                                                                                        (0.34--0.87)                                                                                                                                          0.54                                                                                         (0.31--0.93)           0.51   (0.28--0.94)           0.73   (0.48--1.11)   
   Having had an AIDS defining illness                                                                                                                                                                                                                             0.899                                                                                                                                                                 0.777                         0.888                         0.995
    No                                                                     REF                                                                                                                                                                                                                                               REF                                                                                                                 REF                           REF                   
    Yes                                                                    0.98                                                                                        (0.73--1.32)                                                                                                                                          0.95                                                                                         (0.66--1.37)           1.03   (0.69--1.53)           1.00   (0.76--1.32)   

\(1\) High-grade squamous intraepithelial lesion vs. no squamous intraepithelial lesion; (2) Anal intraepithelial neoplasia 2 vs. no squamous intraepithelial lesion; (3) Anal intraepithelial neoplasia 3 vs. no squamous intraepithelial lesion; (4) High-grade squamous intraepithelial lesion vs. no high-grade squamous intraepithelial lesion (including anal intraepithelial neoplasia 1)[^f^](#TF2-6){ref-type="table-fn"}.

CI, confidence interval; HRA, high-resolution anoscopy; HSIL, high-grade squamous intraepithelial lesion; IQR, interquartile range; SIL, squamous intraepithelial lesion; STD, sexually transmitted disease.

^a^Multivariable model HSIL vs. no SIL includes 1120 participants; multivariable model AIN2 vs. no SIL includes 929 participants; multivariable model AIN3 vs. no SIL includes 847 participants; multivariable model HSIL vs. no HSIL includes 1480 participants.

^b^Per 10-year increase in age.

^c^Per 100 cells/μl increase.

^d^Viral suppression was defined as having a viral load of less than 200 in tests from 1 August 1999 onwards allowing for a onetime blip in viral load between 200 and 400 copies/ml. For samples tested prior to 1 August 1999 the cut-off of detectability of the laboratory assay that was used for that sample is the cut-off for viral suppression. This varies by time period (sensitivity of the assays increased over time) and hospital (based on the used assay).

^e^Participants who never had an undetectable viral load are included in the category less than 1-year undetectable viral load.

^f^Individuals were nested within clinic where HRA was done (multilevel analysis).
